NCT04061980View on ClinicalTrials.gov

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2027

Conditions
BRAF NP_004324.2:p.V600MBRAF V600E Mutation PresentMetastatic Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaStage IV Differentiated Thyroid Gland Carcinoma AJCC v8Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
Interventions
DRUG

Binimetinib

Given PO

DRUG

Encorafenib

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

97213

Providence Portland Medical Center, Portland

All Listed Sponsors
collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

lead

Providence Health & Services

OTHER